Rituximab depletion of intrahepatic B cells to control refractory hepatic autoimmune overlap syndrome

Learning points for cliniciansHepatic autoimmune overlap syndromes should be considered in patients with evidence of more than one autoimmune hepatic disease.Disease resistant to standard immunosuppression and treatment of cholestasis can progress rapidly to cirrhosis and associated complications.Specialist input and treatment with novel therapies, such as B-cell depleting agents, present an opportunity to achieve disease remission in refractory cases.
Source: QJM - Category: Internal Medicine Source Type: research